DK181484A - Middel mod svulster og fremgangsmaade til fremstilling deraf - Google Patents

Middel mod svulster og fremgangsmaade til fremstilling deraf Download PDF

Info

Publication number
DK181484A
DK181484A DK181484A DK181484A DK181484A DK 181484 A DK181484 A DK 181484A DK 181484 A DK181484 A DK 181484A DK 181484 A DK181484 A DK 181484A DK 181484 A DK181484 A DK 181484A
Authority
DK
Denmark
Prior art keywords
preparation
means against
against tumors
tumors
Prior art date
Application number
DK181484A
Other languages
Danish (da)
English (en)
Other versions
DK181484D0 (da
Inventor
Yoshiharu Oguchi
Koishi Niimura
Takayoshi Fujii
Masahiko Fujii
Kenichi Matsunaga
Chikao Yoshikumi
Original Assignee
Kureha Chemical Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kureha Chemical Ind Co Ltd filed Critical Kureha Chemical Ind Co Ltd
Publication of DK181484D0 publication Critical patent/DK181484D0/da
Publication of DK181484A publication Critical patent/DK181484A/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/809—Drug, bio-affecting and body treating compositions involving immunoglobulin or antibody fragment, e.g. fab', fv, fc, heavy chain or light chain
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK181484A 1983-04-08 1984-04-06 Middel mod svulster og fremgangsmaade til fremstilling deraf DK181484A (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP58061923A JPS59186924A (ja) 1983-04-08 1983-04-08 ヒト免疫グロブリン結合抗腫瘍剤

Publications (2)

Publication Number Publication Date
DK181484D0 DK181484D0 (da) 1984-04-06
DK181484A true DK181484A (da) 1984-10-09

Family

ID=13185161

Family Applications (1)

Application Number Title Priority Date Filing Date
DK181484A DK181484A (da) 1983-04-08 1984-04-06 Middel mod svulster og fremgangsmaade til fremstilling deraf

Country Status (7)

Country Link
US (2) US4738843A (cg-RX-API-DMAC7.html)
EP (1) EP0122132A3 (cg-RX-API-DMAC7.html)
JP (1) JPS59186924A (cg-RX-API-DMAC7.html)
CA (1) CA1301066C (cg-RX-API-DMAC7.html)
DK (1) DK181484A (cg-RX-API-DMAC7.html)
SE (2) SE462261B (cg-RX-API-DMAC7.html)
ZA (1) ZA842272B (cg-RX-API-DMAC7.html)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0653682B2 (ja) * 1983-04-08 1994-07-20 呉羽化学工業株式会社 ヒト免疫グロブリン結合抗腫瘍剤
CA1260828A (en) * 1983-07-04 1989-09-26 Masakazu Iwai Therapeutic and prophylactic agent for gastrointestinal ulcers
FR2581313A1 (fr) * 1985-05-02 1986-11-07 Pasteur Institut Composes suscitant la formation d'anticorps, compositions immunogeniques et compositions immunoprotectrices les contenant et procede d'obtention d'anticorps les mettant en oeuvre
JPS63502112A (ja) * 1986-01-03 1988-08-18 コンソリデイテツド・フアーマシユーテイカルズ・リミテツド メルファラン誘導体
CA1330378C (en) * 1986-05-08 1994-06-21 Daniel J. Coughlin Amine derivatives of folic acid analogs
JPH0662438B2 (ja) * 1986-08-28 1994-08-17 帝人株式会社 殺細胞性抗体複合体及びその製造方法
EP0279862B1 (en) * 1986-08-28 1993-11-03 Teijin Limited Cytocidal antibody complex and process for its preparation
YU46858B (sh) * 1987-03-11 1994-06-24 Farmitalia Carlo Erba S.R.L. Postupak za dobijanje imunoglobulinskih konjugata
US4900547A (en) * 1987-10-23 1990-02-13 University Of British Columbia Method to immunize mammals against tumors
GB8727157D0 (en) * 1987-11-19 1987-12-23 Wellcome Found Pharmaceutical formulations
US4994440A (en) * 1989-02-13 1991-02-19 Creaven Patrick J Method for the treatment of renal cell carcinoma
US6326467B1 (en) * 1989-02-23 2001-12-04 Colorado State University Research Foundation Hormone-recombinant toxin compounds and methods for using same
CA2021942C (en) * 1989-08-10 2001-04-10 Michel Page Coupling of an anti-tumor to an antibody using glutaraldehyde preactivated anti-tumor agent
GB2246779B (en) * 1990-08-03 1994-08-17 Delta Biotechnology Ltd Tumour-associated protease inhibitors targeted to tumour cells
ATE127018T1 (de) * 1992-03-06 1995-09-15 Fiutowski Zdzislaw Pharmazeutische zusammensetzung mit antiviraler und antibakterieller wirkung.
JP2578044B2 (ja) * 1992-03-14 1997-02-05 呉羽化学工業株式会社 フェニルアラニン−グリシン誘導体、その製造方法、及びその誘導体を含有する抗腫瘍剤
JPH08504824A (ja) * 1992-12-21 1996-05-28 オフィディアン ファーマシューティカルズ，インコーポレーテッド 敗血症の予防および治療
EP0608546A3 (en) * 1992-12-22 1995-09-27 Takeda Chemical Industries Ltd Glia activating factor (gaf), antibodies against it and their uses.
US5382582A (en) * 1993-03-26 1995-01-17 Chan; Carcy L. Methotrexate analogs and methods of using same
US5502037A (en) * 1993-07-09 1996-03-26 Neuromed Technologies, Inc. Pro-cytotoxic drug conjugates for anticancer therapy
US5698556A (en) * 1995-06-07 1997-12-16 Chan; Carcy L. Methotrexate analogs and methods of using same
US6441025B2 (en) * 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
AU3276297A (en) * 1996-06-27 1998-01-14 Chugai Seiyaku Kabushiki Kaisha Remedies for myeloma to be used together with nitrogen mustard antitumor agents
WO2006031614A2 (en) * 2004-09-10 2006-03-23 Tosk, Inc. Reduced toxicity methotrexate formulations and methods for using the same
WO2007035624A1 (en) * 2005-09-20 2007-03-29 Amgen Inc. Method for generating f(ab')2 antibody fragments
CN101355952B (zh) 2005-11-28 2012-03-21 韦罗制药有限公司 用于减少肾毒性的组合物及其使用方法
ATE432955T1 (de) 2005-12-05 2009-06-15 Nitto Denko Corp Polyglutamat-aminosäure-konjugate und verfahren
US20080181852A1 (en) * 2007-01-29 2008-07-31 Nitto Denko Corporation Multi-functional Drug Carriers
CN101674852A (zh) * 2007-04-10 2010-03-17 日东电工株式会社 多功能聚谷氨酸盐药物载体
CA2683590A1 (en) 2007-05-09 2008-11-20 Nitto Denko Corporation Compositions that include a hydrophobic compound and a polyamino acid conjugate
CN101707869A (zh) * 2007-05-09 2010-05-12 日东电工株式会社 具有多种药物的聚谷氨酸盐结合物和聚谷氨酸盐-氨基酸结合物
EP2155254B1 (en) * 2007-05-09 2012-11-28 Nitto Denko Corporation Polymers conjugated with platinum drugs
CN102014919B (zh) 2008-03-03 2015-02-25 托斯克公司 减少毒性的甲氨蝶呤佐剂及其使用方法
JP2011513412A (ja) * 2008-03-06 2011-04-28 日東電工株式会社 ポリマーパクリタキセル結合体を含む癌を治療するための薬学組成物
AR077384A1 (es) 2010-07-05 2011-08-24 Eriochem Sa Una formulacion farmaceutica inyectable de melfalano.
MX367055B (es) 2012-06-26 2019-08-02 Del Mar Pharmaceuticals El uso de una composición que comprende dianhidrogalactitol, diacetildianhidrogalactitol, y dibromodulcitol, y análogos o derivados de cada uno para el tratamiento de malignidades resistentes a inhibidores de tirosina cinasa.
CN105492011A (zh) 2013-04-08 2016-04-13 丹尼斯·M·布朗 不理想给药化学化合物的治疗增效
US10723160B2 (en) 2018-01-23 2020-07-28 Ferro Corporation Carbide, nitride and silicide enhancers for laser absorption
US10854554B2 (en) 2018-01-23 2020-12-01 Ferro Corporation Carbide, nitride and silicide enhancers for laser absorption

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1509707A (en) * 1974-09-20 1978-05-04 Searle & Co Immunological compounds
GB1541435A (en) * 1975-02-04 1979-02-28 Searle & Co Immunological materials
IL47372A (en) * 1975-05-27 1979-10-31 Yeda Res & Dev Fab'dimers bound to daunomycin or adriamycin,their preparation and pharmaceutical compositions containing same
US4263279A (en) * 1975-08-19 1981-04-21 Yeda Research & Development Co. Ltd Pharmaceutically active compositions containing adriamycin and daunomycin
US4017471A (en) * 1975-09-15 1977-04-12 G. D. Searle & Co. Immunological compounds
JPS5364617A (en) * 1976-11-22 1978-06-09 Furukawa Electric Co Ltd:The Manufacture of oxygen-free high-conductivity copper
JPS54132503A (en) * 1978-04-07 1979-10-15 Kayaku Antibiotic Research Co Immune globulin combined neocarcinostatin
FR2437213A1 (fr) * 1978-09-28 1980-04-25 Cm Ind Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation
US4493793A (en) * 1978-12-26 1985-01-15 E-Y Laboratories Soluble immunoassay reagent comprising lectin covalently bonded to reactive component
US4315851A (en) * 1978-12-29 1982-02-16 Kureha Kagaku Kogyo Kabushiki Kaisha Pharmaceutical composition having antitumor activity
JPS5616418A (en) * 1979-07-20 1981-02-17 Teijin Ltd Antitumor protein complex and its preparation
US4359457A (en) * 1980-09-30 1982-11-16 Neville Jr David M Anti Thy 1.2 monoclonal antibody-ricin hybrid utilized as a tumor suppressant
FR2504010B1 (fr) * 1981-04-15 1985-10-25 Sanofi Sa Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation
US4489710A (en) * 1981-06-23 1984-12-25 Xoma Corporation Composition and method for transplantation therapy
JPH0651643B2 (ja) * 1983-01-19 1994-07-06 帝人株式会社 殺細胞性修飾免疫グロブリン及びその製造方法

Also Published As

Publication number Publication date
JPS59186924A (ja) 1984-10-23
SE462261B (sv) 1990-05-28
SE8401942D0 (sv) 1984-04-06
DK181484D0 (da) 1984-04-06
EP0122132A2 (en) 1984-10-17
CA1301066C (en) 1992-05-19
SE8401942L (sv) 1984-11-13
ZA842272B (en) 1984-11-28
SE8904004D0 (sv) 1989-11-27
EP0122132A3 (en) 1985-11-27
US4925662A (en) 1990-05-15
US4738843A (en) 1988-04-19
JPS6330289B2 (cg-RX-API-DMAC7.html) 1988-06-17
SE8904004L (sv) 1991-05-28

Similar Documents

Publication Publication Date Title
DK181484A (da) Middel mod svulster og fremgangsmaade til fremstilling deraf
DK165321C (da) Oxiranderivater og fremgangsmaade til fremstilling deraf
DK256485A (da) Veterinaert praeparat og fremgangsmaade til fremstilling deraf
DK227884A (da) 1-pyrimidinyloxy-3-hetarylalkylamino-2-propanoler, deres fremstilling og anvendelse
DK594884D0 (da) Tvaerbundne polymerisater, deres fremstilling og anvendelse
DK483083A (da) Platin-diamin komplekser og fremgangsmaade til fremstilling deraf
NO845266L (no) Laminert polyesterholdig substrat og anvendelse derav
DK621484D0 (da) Acylaminomitosaner og fremgangsmaade til fremstilling deraf
DK343684D0 (da) Phenyletherderivater og fremgangsmaade til fremstilling deraf
DK406384D0 (da) Imidazobenzodiazepinderivater og disses anvendelse
DK445784A (da) Fluorenylalkylimidazol-derivater og fremgangsmaade til fremstilling deraf
DK596784D0 (da) Phenylderivater og fremgangsmaade til fremstilling deraf
DK135684A (da) 2-cyano-imidazopyridin-derivater og fremgangsmaade til fremstilling heraf
DK26384A (da) Toxoplasmosefaktor og fremgangsmaade til fremstilling deraf
DK140684D0 (da) Phenethanolaminer og deres anvendelse
DK454684D0 (da) 7beta-acylamino-3-azido-cephalosporiner og fremgangsmaade til fremstilling heraf
DK454784D0 (da) 6-oxodecahydroquinoliner og fremgangsmaade til fremstilling heraf
DK513784D0 (da) Iodacetamider, deres fremstilling og anvendelse til skadedyrsbekaempelse
DK552284A (da) 2-chlor-3-trifluormethylbenzaldehyd og fremgangsmaade til fremstilling deraf
NO845134L (no) Dialkanoyloksybenzyliden-dialkanoat og fremgangsmaate til fremstilling derav.
DK284184A (da) 1-phenoxy-3-hydroxyindolylalkylamino-3-propanoler og fremgangsmaade til fremstilling deraf
DK596884D0 (da) Phenylderivater og fremgangsmaade til fremstilling deraf
DK187484D0 (da) Naphthylglycyl-og tetrahydronaphthylglycyl-cephalosporin-antibiotika og fremgangsmaade til fremstilling heraf
DK550883D0 (da) Hexahydrodioxopyrimidiner og fremgangsmade til fremstilling deraf
DK161315C (da) Trans-d,1-1-alkyl-6-alkoxy-octahydroquinoliner og fremgangsmaade til fremstilling heraf

Legal Events

Date Code Title Description
AHS Application shelved for other reasons than non-payment